Qiagen (NYSE:QGEN) Releases Q1 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its first quarter earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of at least $0.55 for the period, compared to the consensus estimate of $0.49. The company issued revenue guidance of ~$483 million, compared to the consensus revenue estimate of $464.42 million. Qiagen also updated its FY 2025 guidance to 2.350- EPS.

Qiagen Stock Down 5.3 %

Shares of NYSE:QGEN opened at $38.24 on Monday. Qiagen has a fifty-two week low of $37.63 and a fifty-two week high of $49.30. The firm’s 50 day moving average price is $40.27 and its 200 day moving average price is $41.94. The company has a quick ratio of 3.09, a current ratio of 3.61 and a debt-to-equity ratio of 0.38. The stock has a market cap of $8.50 billion, a price-to-earnings ratio of 106.48, a price-to-earnings-growth ratio of 2.39 and a beta of 0.62.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. As a group, equities research analysts predict that Qiagen will post 2.26 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on QGEN shares. Jefferies Financial Group reissued a “buy” rating and set a $52.50 target price (up previously from $40.83) on shares of Qiagen in a research report on Tuesday, December 10th. Redburn Atlantic cut shares of Qiagen from a “buy” rating to a “neutral” rating in a research report on Friday. Robert W. Baird lowered Qiagen from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $52.00 to $42.00 in a report on Wednesday, February 19th. UBS Group cut their target price on Qiagen from $50.00 to $48.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. Finally, Baird R W cut Qiagen from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 19th. Eight equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $47.71.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.